ModifiedUnitedHealthcarePolicy CS082OH.E

Neurophysiologic Testing and Monitoring (for Ohio Only)

Medical policy governing neurophysiologic testing and monitoring services for UnitedHealthcare members in Ohio, including which tests are considered proven/medically necessary and which are unproven/not medically necessary.

Policy Summary

PayerUnitedHealthcare

PolicyNeurophysiologic Testing and Monitoring (for Ohio Only)

Policy CodePolicy CS082OH.E

Change TypeCoverage clarification and additions

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionFollow Ohio Administrative Code and document clinical indication, performing NCS with needle EMG for listed disorders or NCS-alone only for specified exceptions (anticoagulation, lymphedema, carpal tunnel evaluation).

SourceLink

POLICY UPDATE CHANGES

Added language specifying that nerve conduction studies with or without standard late responses and for neuromuscular junction testing when performed with needle EMG are proven and medically necessary for a list of known or suspected disorders.

Clarified that NCS with or without standard late responses when performed without needle EMG are medically necessary for individuals with anticoagulation, lymphedema, or evaluation for carpal tunnel syndrome.

Declared nerve conduction studies for all other conditions and non-invasive automated point-of-care devices that test only distal motor latencies/conduction velocities as unproven and not medically necessary.

Added language that nerve conduction studies with or without standard late responses and for neuromuscular junction testing when performed with needle EMG are proven and medically necessary for listed disorders (peripheral neuropathy, plexopathy, myopathy, motor neuron disease, radiculopathy, treatment guidance).

Clarified that nerve conduction studies with or without standard late responses performed without needle EMG are medically necessary for individuals on anticoagulants, with lymphedema, or being evaluated for carpal tunnel syndrome.

Specified that nerve conduction studies for all other conditions and non-invasive automatic/portable point-of-care devices testing only distal motor latencies/conduction velocities are unproven and not medically necessary.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

1state-specific (OH)

6proven indications

3NCS-alone exceptions

8+unproven/tests

05/01/2026document revision

Coverage Criteria — Neurophysiologic Testing and Monitoring

inv-01: Proven / Medically Necessary Testing

Covered when ALL of the following are met:

General coverage: Neurophysiologic testing and monitoring are proven and medically necessary in certain circumstances for members 18 years and older; refer to InterQual CP: Procedures, Electromyography (EMG) and Nerve Conduction Studies (NCS) for medical necessity clinical coverage criteria.

Reference to InterQual for detailed criteria

Indications for NCS with/without standard late responses and with needle EMG: NCS with or without standard late responses and performed in conjunction with needle EMG is medically necessary for suspected or known peripheral neuropathy/polyneuropathy, plexopathy, neuromuscular junction disorders, myopathy, motor neuron disease, radiculopathy (cervical, thoracic, or lumbosacral), and for treatment guidance such as muscle localization for botulinum toxin injections.

NCS without needle EMG allowed: Nerve conduction studies with or without standard late responses when performed without needle electromyography are medically necessary for individuals who are treated with anticoagulants, individuals with lymphedema, or individuals being evaluated for carpal tunnel syndrome.

inv-02: Unproven / Not Medically Necessary

Not medically necessary (unproven) when ANY of the following apply:

Unproven tests list: Macroelectromyography (macro-EMG); non-invasive automatic/portable/automated point-of-care nerve conduction monitoring systems that test only distal motor latencies and conduction velocities; physiologic monitoring of seizure and/or movement disorders using wearable devices with accelerometers, electrodermal sensors, or gyroscopes (e.g., wrist-devices, smartwatches); SEMG-based seizure monitoring systems; surface electromyography (SEMG); surface mechanomyography (sMMG); quantitative sensory testing including monofilament, pressure-specified sensory testing, computer assisted sensory examinations, and current perception threshold (CPT) testing; and visual evoked potential testing for diagnosing/evaluating glaucoma.

These items are listed as unproven and not medically necessary due to insufficient evidence of efficacy.

inv-03: AANEM-based indications and performance criteria

Covered when ALL of the following are met (per AANEM guidance):

EDX Indication and performance: EDX testing (nerve conduction studies and needle electromyography) is indicated for focal entrapment neuropathies, traumatic nerve lesions, generalized neuropathies, polyneuropathies, neuromuscular junction disorders, myopathies, motor neuron disease, radiculopathy, plexopathy, and for precise muscle localization for injections (e.g., botulinum toxin) when clinically indicated.

Source: AANEM model policy and literature summary

Testing standards: Testing must be medically indicated, performed using equipment that assesses all signal parameters (screening equipment not acceptable), performed by a physician or by a trained technician under the direct supervision of a physician, with needle EMG performed by a trained physician and one physician supervising and performing all components as required by AANEM standards.

Source: AANEM minimum standards (2014, updated 2023)

When NCS alone may be acceptable: Per AANEM, nerve conduction studies may be performed without needle EMG in individuals on anticoagulants, individuals with lymphedema, or when evaluating for carpal tunnel syndrome.

inv-04: EDX consideration in distal symmetric polyneuropathy

Consider EDX testing when ANY of the following are present:

When to consider EDX in DSP: History, physical, and standard neuropathy blood tests do not indicate a likely etiology; symptoms or physical findings are moderate to severe; atypical presentation (predominantly motor symptoms/findings, proximal deficits, or asymmetry); rapid progression of signs or symptoms; presence of signs suggesting another disorder (e.g., radiculopathy); unknown duration or severity; family history suggesting hereditary neuropathy; exposure to neurotoxic substances or medications; or discrepancy between signs and symptoms.

AANEM distal symmetric polyneuropathy guidance

inv-05: Evidence-based considerations

Guidance and evidence summary indicating when use may be supported or is limited:

Wearable seizure detection (GTCS/FBTCS): ILAE-IFCN recommends using clinically validated wearable devices for automated detection of generalized tonic-clonic seizures (GTCS) and focal bilateral tonic-clonic seizures (FBTCS) when significant safety concerns exist and alarms can enable rapid intervention (within ~5 minutes); current recommendations are conditional and do not support use for other seizure types.clinical validation demonstrated

Recommendation is weak/conditional

QST limitations: AAN and AANEM note that quantitative sensory testing (QST) demonstrates variable sensitivity and specificity across studies, is highly dependent on methodology and subject cooperation, and should not be used as the sole diagnostic method; vibration and thermal thresholds have some support for diabetic neuropathy but overall reproducibility and standardization are limited.not sole diagnostic test

Practice parameters caution methodological variability and limited generalizability

inv-06: Evidence summaries relevant to coverage

Evidence-based summaries and professional society positions relevant to coverage determinations:

QST Evidence: Professional societies report wide variability and inconsistent reproducibility of QST across studies; methodological dependence and need for strict calibration and protocol adherence limit incorporation into routine diagnostic case definitions.

AAN and AANEM practice topics/reviews

sNCT/sensory nerve conduction threshold: AANEM model policy designates current perception threshold/sensory nerve conduction threshold testing (sNCT) as investigational.

Investigational designation may affect coverage decisions

sEMG Clinical Utility: Evidence for surface EMG (sEMG) and SEMG-based seizure monitoring shows feasibility for GTCS detection but is limited by variable sensitivity, high false alarm rates, low positive predictive value in some studies, and device tolerability concerns; larger standardized trials are needed.

Phase III trial (Halford et al.) showed feasibility but high FAR and low PPV

inv-07: Medically necessary indications

Covered when the following conditions are met:

Medically necessary NCS+EMG indications: Nerve conduction studies with or without standard late responses and neuromuscular junction testing when performed in conjunction with needle electromyography are proven and medically necessary for known or suspected: peripheral neuropathy/polyneuropathy (inherited, metabolic, traumatic, entrapment syndromes); plexopathy; myopathy; motor neuron disease; radiculopathy (cervical, thoracic, or lumbosacral); and for treatment guidance such as muscle localization for botulinum toxin injections when required to identify affected muscles warranting injection.

From policy revision 05/01/2026

Medically necessary NCS-alone indications: Nerve conduction studies with or without standard late responses when performed without needle electromyography are considered medically necessary for individuals who are anticoagulated, individuals with lymphedema, and individuals being evaluated for carpal tunnel syndrome.

From policy revision 05/01/2026

inv-08: Unproven / Not Medically Necessary

Not medically necessary / unproven when the following conditions apply:

Unproven NCS indications: Nerve conduction studies performed for conditions other than the listed known or suspected disorders are considered unproven and not medically necessary due to insufficient evidence of efficacy.

From policy revision 05/01/2026

Unproven point-of-care devices: Non-invasive automatic, portable, or automated point-of-care nerve conduction monitoring systems that test only distal motor latencies and conduction velocities for electrodiagnostic testing are considered unproven and not medically necessary.

From policy revision 05/01/2026

inv-09: Proven indications when performed with needle EMG

Nerve conduction studies with or without standard late responses and for neuromuscular junction testing when performed in conjunction with needle electromyography are proven and medically necessary for any of the following known or suspected disorders:

Proven indications with needle EMG: Peripheral neuropathy/polyneuropathy (e.g., inherited, metabolic, traumatic, entrapment syndromes); Plexopathy; Neuromuscular junction disorders (e.g., myasthenia gravis); Myopathy; Motor neuron disease; Radiculopathy (cervical, thoracic, or lumbosacral); Treatment guidance (e.g., muscle localization for botulinum toxin injections when required to identify affected muscles warranting injection)

Performed in conjunction with needle EMG

inv-10: Indications permitting NCS without needle EMG

Nerve conduction studies with or without standard late responses when performed without needle electromyography are medically necessary for individuals with any of the following clinical indications:

Permitted without needle EMG: Individuals treated with anticoagulants; Individuals with lymphedema; Individuals being evaluated for carpal tunnel syndrome.

Allows NCS without needle EMG in these specified clinical scenarios

This policy does not address intraoperative neurophysiologic testing. The statement clarifies that intraoperative monitoring and related procedures are outside the scope of this document and are not considered by the coverage rules herein.

Macro-electromyography (macro-EMG) and preliminary automatic or portable point-of-care nerve conduction tests have limited and weak evidence supporting clinical benefit; available studies are small and primarily compare portable systems to conventional testing without demonstrating consistent patient‑relevant outcomes. Physiologic recording and wearable devices for seizure or movement disorder monitoring (including accelerometer, electrodermal, or gyroscope-based wrist devices and smartwatches) show promising feasibility in select studies but overall evidence is heterogeneous and insufficient to support broad clinical coverage without further study.

The ILAE‑IFCN working group issues a conditional recommendation to use clinically validated wearable devices only for automated detection of generalized tonic‑clonic seizures (GTCS) and focal bilateral tonic‑clonic seizures (FBTCS) when significant safety concerns exist (for example, unsupervised individuals who do not share a bedroom) and when alarms can trigger rapid intervention (within ~5 minutes). The ILAE‑IFCN does not recommend clinical use of currently available wearables for other seizure types at this time.

The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) model policy identifies current perception threshold / sensory nerve conduction threshold testing (sNCT) as investigational. As an investigational test, sNCT/perception threshold testing may be excluded from coverage under this policy.

Non‑invasive automated or portable point-of-care nerve conduction monitoring systems that only measure distal motor latencies and conduction velocities (without producing full, interpretable waveforms and signal parameters) are explicitly categorized as unproven and not medically necessary for electrodiagnostic testing. These devices are not considered an acceptable substitute for standard nerve conduction studies performed with appropriate equipment and interpretation.

Nerve conduction studies performed for conditions other than the specific, listed known or suspected disorders are considered unproven and not medically necessary due to insufficient evidence of efficacy. Likewise, non‑invasive automatic, portable, or automated point‑of‑care NCS devices that only report distal motor latencies and conduction velocities are treated as unproven and not medically necessary in this policy.

Examples of procedures and technologies listed in the policy as unproven or not medically necessary include: macro‑EMG, surface electromyography (SEMG) and SEMG‑based seizure monitoring systems, sMMG (surface mechanomyography) often used with IMUs, quantitative sensory testing (QST) modalities such as monofilament and pressure‑specified sensory testing, visual evoked potential (VEP) testing for glaucoma (including isolated‑check VEP methods), and non‑invasive point‑of‑care NCS devices that test only distal motor latencies and conduction velocities.

Devices marketed for simplified nerve conduction assessment (for example, the Nervepace Digital Electroneurometer and similar point‑of‑care electroneurometers) are considered experimental in the absence of robust evidence and are not an acceptable substitute for comprehensive, clinician‑performed electrodiagnostic studies (NCS with needle EMG) when those studies are indicated.

Monofilament testing demonstrates limited sensitivity for detecting diabetic peripheral neuropathy; a pooled analysis found a sensitivity of 0.53 and specificity of 0.88. Given this limited sensitivity, monofilament testing should not be used as the sole diagnostic or screening method for diabetic peripheral neuropathy.

Current evidence for sEMG across many diagnostic indications is limited and variable; surface mechanomyography (sMMG) used with inertial measurement units lacks sufficient published outcome data, and visual evoked potentials for glaucoma (including icVEP) show promising but heterogeneous diagnostic results. Overall, these technologies presently have limited or uncertain evidence to support routine coverage and are described as investigational or not medically necessary pending further high‑quality studies.

Nerve conduction studies requested for conditions that are not among the policy’s specified known or suspected disorders are designated unproven and not medically necessary. Similarly, the use of non‑invasive, automatic, portable, or automated point‑of‑care NCS systems that only report distal motor latencies and conduction velocities is considered unproven and not medically necessary.

This policy limits acceptable use of point‑of‑care NCS devices: devices that only test distal motor latencies and conduction velocities without full waveform assessment are explicitly considered unproven and not medically necessary. In addition, nerve conduction studies performed for indications not listed among the policy’s proven diagnoses are unproven and not medically necessary and may be denied.

Coding — CPT, HCPCS, and Other Codes

Quantitative Sensory Testing CPT II/OtherCPT

0106T	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation.
0107T	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation.
0108T	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia.
0109T	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia.

EMG/NCS and related CPT codesCPT

0110T	QST per extremity; using other stimuli to assess sensation.
0464T	Visual evoked potential, testing for glaucoma, with interpretation and report.
0778T	Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function.
95860	Needle electromyography; 1 extremity with or without related paraspinal areas.
95861	Needle electromyography; 2 extremities with or without related paraspinal areas.
95863	Needle electromyography; 3 extremities with or without related paraspinal areas.
95864	Needle electromyography; 4 extremities with or without related paraspinal areas.
95865	Needle electromyography; larynx.
95866	Needle electromyography; hemidiaphragm.
95867	Needle electromyography; cranial nerve supplied muscle(s), unilateral.

1–10 of 30

1/3

HCPCS and miscellaneous codesHCPCS

A9280	Alert or alarm device, not otherwise classified.
G0255	Current perception threshold/sensory nerve conduction test (SNCT), per limb, any nerve.
S3900	Surface electromyography (EMG).

FDA product codes mentionedmixed

IKN	FDA product code referenced for EMG devices
GWE	FDA product code referenced for evoked response photic stimulators
HLX	FDA product code referenced for evoked response photic stimulators
GWQ	FDA product code referenced for EEG recording devices
LLN	FDA product code referenced for vibration threshold measurement device / QST
GXB	FDA product code referenced for esthesiometer / QST
LQW	FDA product code referenced for temperature discrimination test / QST
GWI	FDA product code referenced for 2-point discriminator / QST
JXE	FDA product code referenced for point of care nerve conduction devices
POS	FDA product code referenced for physiologic recording of movement/seizure monitoring

1–10 of 11

1/2

inv-27: Needle EMG inclusion

RequirementWhen performing neuromuscular junction testing with needle EMG, at least one distal and one proximal muscle should be studied by needle EMG.

ContextApplies to nerve conduction studies and neuromuscular junction testing performed in conjunction with needle electromyography as part of a complete EDX evaluation.

PurposeEnsures adequate sampling to distinguish focal versus generalized neuromuscular junction or muscle disorders and to complement nerve conduction data.

inv-28: PKG wear duration

Minimum wear duration>= 6 days (patients wore the PKG data logger for ≥ 6 days in cited studies).

Provider Actions — Authorization, Documentation, and Denial Risks

Note

State-Level Medical Necessity and Policy Use

This policy applies only to the state of Ohio. Requests for services that are stated as unproven or services subject to a coverage or quantity limit will be evaluated for medical necessity using Ohio Administrative Code 5160-101. Before applying this policy, reference and follow applicable federal, state (OAC), or contractual benefit plan requirements; in the event of a conflict, those requirements govern.

State-level medical necessity evaluation: Ohio Administrative Code 5160-101 will be used to evaluate requests for services listed as unproven or subject to limits.
Reference benefit and guideline requirements: verify applicable federal, state (OAC), or contractual plan terms before applying this policy; UnitedHealthcare uses InterQual® and may use internal policies as permitted.

Prior Authorization

Prior authorization requirements are not specified within the excerpt of this policy. Providers should follow their plan's prior authorization processes and check applicable benefit plan rules or UnitedHealthcare tools for authorization needs.

Background and Context

An overview of neurophysiologic testing modalities: electrodiagnostic studies (NCS and needle EMG) assess peripheral nerve and muscle function and are usually performed together for comprehensive evaluation. Wearable physiologic monitoring and automated detection systems have demonstrated technical feasibility for seizure and movement detection in select studies, and professional societies (ILAE‑IFCN) conditionally recommend validated devices for detecting GTCS/FBTCS in settings with safety concerns; however, evidence is heterogeneous and broader clinical application is limited pending further validation.

Definitions

inv-55: SEMG

DefinitionSurface electromyography (SEMG/sEMG) is a noninvasive technique using electrodes placed on the skin to record electrical activity of underlying muscle.

Scope of usesUsed to monitor muscle function, paraspinal EMG for back pain evaluation, and SEMG-based seizure monitoring systems placed over muscles (e.g., biceps) to detect generalized tonic‑clonic seizures.

LimitationsEvidence for diagnostic efficacy is weak for many SEMG indications; further studies needed to demonstrate consistent patient‑relevant outcomes.

inv-56: Non-invasive automated point-of-care NCS device

DefinitionNon-invasive automated point-of-care NCS device: a portable system using surface electrodes and built-in software to quickly evaluate peripheral nerve function without producing real-time waveforms.

Distinguishing feature

Policy Revision History

2026-05-01policy_revisionLatest

Revised coverage rationale: specified that nerve conduction studies (with or without standard late responses) and neuromuscular junction testing performed with needle EMG are proven and medically necessary for listed disorders (peripheral neuropathy/polyneuropathy, plexopathy, myopathy, motor neuron disease, radiculopathy, and for treatment guidance); clarified that NCS (with or without standard late responses) may be performed without needle EMG for individuals who are anticoagulated, have lymphedema, or are being evaluated for carpal tunnel syndrome; designated NCS for all other conditions and non-invasive point-of-care devices that test only distal motor latencies/conduction velocities as unproven and not medically necessary.

Policy Summary

PayerUnitedHealthcare

PolicyNeurophysiologic Testing and Monitoring (for Ohio Only)

Policy CodePolicy CS082OH.E

Change TypeCoverage clarification and additions

Effective DateMay 1, 2026

Next Review DateN/A

SourceLink

On This Page

Limited exceptions noted

EDX in pediatric/inherited disease: EDX testing is valuable in evaluating inherited neuromuscular diseases in children, especially atypical presentations; centers serving pediatric populations should offer EDX by physicians trained in electrodiagnostics and pediatrics.

AANEM consensus

Wearables and PD monitoring: Objective wearable systems for Parkinson disease (e.g., PKG, KinetiGraph, smartphone sensors, biosensor patches) have shown feasibility and may inform management decisions, but device validation is heterogeneous and larger controlled studies are needed before broad endorsement.device-specific validation

Some studies reported meaningful management impact but evidence is heterogeneous

sMMG and combined IMU systems: Few studies exist for surface mechanomyography (sMMG) with IMUs; current evidence is insufficient to conclude benefit on patient-relevant health outcomes.

Insufficient evidence for routine coverage

icVEP for Glaucoma: Isolated-check VEP (icVEP) demonstrates promising diagnostic performance in pooled analyses (e.g., sensitivity ~77% and specificity ~93% in a 2025 meta-analysis) but study heterogeneity, variable protocols, and limited high-quality trials limit generalizability and definitive coverage recommendations.

Further research needed; device-specific SNR cutoffs vary

Use caseWearable PKG used to collect continuous objective measurements in routine daily living to inform Parkinson disease management.

Documentation expectationWhen device data inform management, documentation should include duration of wear and device-derived findings that influenced management.

inv-29: icVEP SNR cutoff

SNR cutoffs reportedStudies used signal-to-noise ratio (SNR) cutoffs ranging from 0.85 to 1.0 for icVEP classification.

Effect on performanceDifferent SNR cutoffs affected sensitivity and specificity (e.g., cutoff 0.85 vs 1.0 produced varying sensitivity/specificity in Xu et al.).

Method noteSNR is contrast dependent and rises as contrast increases; cutoff selection influences diagnostic accuracy.

Prior authorization not specified in this policy excerpt — check member-specific benefit plan and UnitedHealthcare prior authorization resources.

Denial Risk

Separate NCS Without EMG — Exception Only

Nerve conduction studies (NCS) are generally intended to be performed in conjunction with needle EMG; performing NCS separately from needle EMG should be the exception. Separate NCS without EMG may omit complementary information and could lead to incomplete evaluation or denial unless limited exceptions apply (e.g., anticoagulation, lymphedema, carpal tunnel evaluation).

Separate NCS without EMG is discouraged and should be justified in the record; exceptions include individuals on anticoagulants, with lymphedema, or being evaluated for carpal tunnel syndrome.
Performing NCS and EMG on the same day with a single supervising physician is standard; separate reports for NCS and EMG are generally inappropriate.

Denial Risk

High False Alarm Rates (FAR) — Coverage Risk

Wearable devices for seizure or movement monitoring can have high false alarm rates (FAR). High FARs may be unacceptable in some clinical settings and could influence coverage or lead to denial when the device performance is insufficient for the intended clinical use.

High false alarm rates (FAR) for wearable seizure detection devices may trigger denial or be considered unacceptable for clinical use in some settings.
Assess device sensitivity and FAR on a case-by-case basis; documentation of device performance relevant to the clinical scenario is advised.

Documentation Required

Provider Qualifications for Needle EMG

Needle EMG examinations should be performed by physicians specially trained in electrodiagnostic (EDX) medicine. Providers are expected to have demonstrable training and experience (e.g., appropriate residency/fellowship training and certification such as ABEM) and, when applicable, accreditation of the EDX laboratory is encouraged.

Provider qualifications for EMG: physicians with training in neurology or PMR residencies/fellowships and board certification or equivalent in EDX medicine.
EDX laboratory accreditation is voluntary but indicates adherence to quality and safety standards.

Documentation Required

Documentation and Supervision Requirements

Clinical and electrophysiologic data collection should be supervised by the EDX physician. The physician may delegate data collection to trained technologists or trainees but must be immediately available for NCS/SEP testing and review results. Documentation must support supervision and delegation.

Required clinical documentation and supervision: differential diagnosis based on history/exam, list of NCS and needle EMG components performed, notation of who performed each component, and documentation that the EDX physician supervised and reviewed results.
Physician availability: for NCS/SEP, the EDX physician may be absent from the room but must be immediately available and review results prior to the patient's departure when indicated.

Documentation Required

Device Wear and Physician Documentation

When device-derived data (e.g., PKG) are used to inform management decisions, provider documentation should specify duration of wear, device-derived findings, and the physician's interpretation and how it affected management.

Device wear and physician documentation: record duration of wear (e.g., ≥6 days for PKG when applicable), specific device metrics relied upon, and how those metrics influenced therapeutic decisions or referrals.
Document physician familiarity with device, interpretation rationale, and any limitations of device data.

Documentation Required

Methodology and Calibration Documentation for QST

For quantitative sensory testing (QST) and other sensory threshold tests, include methodology, instrument details, evidence of reproducibility, calibration records, and testing protocol in the medical record. Only reproducible, calibrated instruments and documented protocols should be used.

Methodology and calibration documentation: specify the instrument, thermode size or stimulus characteristics, testing protocol, algorithm, normative values used, and recent calibration/reproducibility evidence.
QST limitations: note dependence on patient cooperation and potential inability to localize lesions.

Note

Use of Validated Wearables for GTCS/FBTCS

Use clinically validated wearable devices for detection of generalized tonic-clonic seizures (GTCS) and focal bilateral tonic-clonic seizures (FBTCS) when significant safety concerns exist, particularly for unsupervised individuals where alarms enable rapid intervention. Current evidence does not support use of wearables for other seizure types.

Use validated devices for GTCS/FBTCS when safety concerns exist; do not use current wearable devices for other seizure types outside research settings.
Document rationale for device selection and the clinical scenario necessitating wearable monitoring.

Step Therapy

Step Approach for NCS With or Without Needle EMG

UnitedHealthcare and specialty society guidance endorse a stepwise approach: NCS with needle EMG is the standard evaluation for listed neuromuscular disorders; exceptions permitting NCS without EMG are limited to specific clinical circumstances (e.g., anticoagulation, lymphedema, carpal tunnel). Document meeting criteria for any exception.

Step approach: perform NCS plus needle EMG when evaluating suspected peripheral neuropathy, plexopathy, neuromuscular junction disorders, myopathy, motor neuron disease, radiculopathy, or for treatment guidance (e.g., botulinum toxin muscle localization).
Exceptions allowing NCS without EMG: individuals on anticoagulants, those with lymphedema, and individuals evaluated for carpal tunnel syndrome — document clinical indication and justification.

These devices typically test distal motor latencies, response amplitudes, and conduction velocities but do not provide real‑time waveforms and are intended for screening rather than full EDX replacement.

Clinical roleMay be used for screening in primary care or remote settings but is not a substitute for comprehensive electrodiagnostic testing by trained personnel.

inv-57: Quantitative Sensory Testing (QST)

DefinitionQuantitative Sensory Testing (QST) is a noninvasive psychophysical method that measures sensory thresholds (touch, vibration, temperature, pressure, pain) to assess peripheral sensory nerve function.

Methods includedIncludes tools such as monofilaments, pressure‑specified sensory testing, computerized systems, current perception threshold (sNCT/CPT) and voltage‑actuated sNCT methods.

LimitationsQST results are methodology‑dependent, require patient cooperation, lack specificity for particular neuropathies, and overall evidence for routine diagnostic use is weak and variable.

inv-58: mfVEP

DefinitionMultifocal visual evoked potential (mfVEP) is a variation of VEP testing that assesses multiple visual field locations independently and concurrently, producing a topographical representation of visual defects.

ApplicationInvestigated for diagnosing and monitoring glaucoma as part of visual pathway assessment.

LimitationsEvidence for VEPs in glaucoma is weak overall; mfVEP is one of several VEP variants studied and requires further validation for routine clinical use.

inv-59: Real time onsite

DefinitionReal-time onsite EDX: integration of clinical history, tailored study performance, and waveform analysis while the patient is present in the laboratory.

Performance expectationsTesting should be performed using equipment that assesses all signal parameters and by qualified personnel; EMG must be performed by a trained physician with direct supervision as required by AANEM standards.

PurposeEnables immediate interpretation, adjustment of the study based on findings, and completion of indicated needle EMG studies to evaluate the differential diagnosis.

inv-60: GTCS/FBTCS

GTCS definitionGeneralized tonic‑clonic seizure (GTCS): a seizure type for which clinically validated wearable detectors are conditionally recommended when safety concerns exist.

FBTCS definitionFocal bilateral tonic‑clonic seizure (FBTCS): focal onset seizures that generalize to bilateral tonic‑clonic activity; also a seizure type for which validated wearables may be used per ILAE‑IFCN guidance.

Clinical noteILAE‑IFCN does not recommend wearables for seizure types other than GTCS/FBTCS pending further research; alarms should permit rapid intervention (~5 minutes) to support use.

inv-61: QST

DefinitionQuantitative Sensory Testing (QST) comprises psychophysical tests that measure thresholds for vibration, thermal (warm/cold), light touch‑pressure, and pain stimuli to assess sensory function.

CharacteristicsResults depend on subject cooperation, instrument specifications, testing protocols, and calibration; reproducibility varies across modalities and devices.

InterpretationAbnormal QST findings are not specific to a particular neuropathy and should not be used as the sole diagnostic method; methodology and longitudinal reproducibility must be considered.

inv-62: Quantitative Sensory Testing (QST)

Psychophysical natureQST is a psychophysical testing approach measuring sensory thresholds; outcomes reflect the integrity of the sensory axis but do not localize dysfunction along the nervous system.

Dependence on cooperationQST is highly dependent on full patient cooperation and may be biased by subject response tendencies or cognitive impairment.

Methodology requirementsOnly QST instruments and methodologies shown to be reproducible should be used; machine calibration and strict protocol adherence are required for valid interpretation.

inv-63: Surface Electromyography (sEMG)

DefinitionSurface Electromyography (sEMG) is the noninvasive recording of muscle electrical activity via electrodes placed on the skin.

UsesUsed for monitoring muscle function, seizure‑related muscle activity (SEMG‑based seizure monitors), and respiratory muscle assessment in some contexts.

Evidence limitationPeer‑reviewed evidence for many sEMG diagnostic applications is weak; further robust studies are needed to establish consistent patient‑relevant outcomes.

inv-64: Surface Mechanomyography (sMMG)

DefinitionSurface Mechanomyography (sMMG) measures mechanical muscle activity using wearable sensors applied across a muscle group, often combined with inertial measurement units (IMUs).

Typical applicationsUsed to assess multi‑joint range of motion, posture, gait, and muscle function; emerging technologies pair sMMG with IMUs for biomechanical evaluation.

Evidence statusFew published studies exist and there is insufficient evidence to conclude a beneficial effect on health outcomes; routine clinical utility is not established.

inv-65: Isolated-check Visual Evoked Potential (icVEP)

DefinitionIsolated‑check Visual Evoked Potential (icVEP) is an electrophysiologic test of the visual pathway that produces a signal‑to‑noise ratio (SNR) metric used to detect glaucomatous dysfunction.

SNR concepticVEP response SNR is contrast dependent and used with predefined cutoffs (e.g., 0.85–1.0) to classify abnormal vs normal responses; cutoff selection affects sensitivity and specificity.

Clinical evidenceMeta‑analysis and cross‑sectional studies report moderate‑to‑high diagnostic performance but heterogeneity and limited sample sizes constrain generalizability.

inv-66: FDA Class II device classification referenced for EMG, VEPs, and other devices

DefinitionFDA Class II device classification applies to many neurophysiologic devices including EMG and VEP systems; manufacturers use specific FDA product codes (e.g., IKN, GWE, HLX).

ImplicationClass II designation indicates device controls are in place and devices are regulated, but clinical performance and intended use should be evaluated per evidence.

ReferencePolicy cites FDA product codes and class II status for EMG and VEP devices (see product codes referenced in policy).

inv-67: icVEP testing method (Neucodia system) — brief method note

Method summaryIn the cited study using the Neucodia system, icVEP testing employed a 15% positive‑contrast condition and swept contrast steps with EEG synchronized to the display frame rate to calculate SNR at the fundamental frequency.

PurposeThis method differentiated glaucoma participants from healthy controls by evaluating contrast‑dependent SNR response functions.

Sample noteStudy used device‑specific protocol (Neucodia) and highlights that device/method differences affect results and generalizability.

inv-68: Standard late responses

DefinitionStandard late responses refer to electrophysiologic tests such as F‑wave and H‑reflex studies that are complementary to nerve conduction velocity testing.

Clinical roleLate responses may be the only abnormality in some cases and provide additional information for radiculopathy and other peripheral nerve disorders.

ExamplesF‑wave (late response evoked by maximal stimulation) and H‑reflex (electrophysiologic component of the ankle reflex) are commonly used late responses.

inv-69: Point-of-care NCS devices

DefinitionPoint‑of‑care NCS devices are non‑invasive, automated, portable nerve conduction monitoring systems that test only distal motor latencies and conduction velocities for the purpose of electrodiagnostic testing.

LimitationsThese devices typically do not produce real‑time waveforms and are intended for screening; the policy identifies devices that test only distal parameters as unproven and not medically necessary for comprehensive electrodiagnostic evaluation.

Clinical implicationNot a substitute for full electrodiagnostic testing performed with appropriate equipment and by trained personnel; may be denied as unproven for diagnostic EDX purposes.